Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2021

View Archived Issues

Human cerebral organoids show utility to evaluate candidate inhibitors of prion accumulation in CJD

Phase III GOBI study of NOV-03 meets statistical significance on coprimary and secondary endpoints

BMC-128 shows promising antitumor activity in mouse model of melanoma

Phase II study of fostamatinib in patients with COVID-19 meets primary endpoint

FDA clears IND application for phase IIb study of AXA-1125 in NASH

Companies report progress of catumaxomab clinical trials for NMIBC

CFT-7455 shows potent tumor regression in IMiD-resistant multiple myeloma xenografts

First-in-class pan-inhibitor of KDM4 TACH-101 active in multiple cancer models

SPH Biotherapeutics presents new isolated antigen-binding proteins

New PARG inhibitors identified at Ideaya Biosciences

Accutar Biotechnology synthesizes new androgen receptor degrading PROTACs

Merck & Co. presents a novel potent, selective and brain-penetrant LRRK2 kinase inhibitor

Merck & Co. discovers KRAS G12C mutant inhibitors

BIAL Biotech discovers acid ceramidase inhibitors

BNT-162b2 and mRNA-1273 achieve only partial cross-neutralization of novel SARS-CoV-2 variants

Longeveron reports final phase I data on Lomecel-B in Alzheimer's disease

Development of human African trypanosomiasis carbazole drugs

New agonist MAb resolves chronic inflammation

New phase II trials evaluate BI-456906 in obesity and NASH

Tilt and MSD agree to study TILT-123 with Keytruda in ovarian cancer

Bispecific antibody targeting LAG-3 and PD-L1 (ABL501) for cancer immunotherapy

Iterion completes enrollment in phase I/IIa dose-expansion study of tegavivint in desmoid tumors

Moderna updates progress of COVID-19 vaccine program

Apellis reports 24-month data from phase Ib study of pegcetacoplan in geographic atrophy

Trodelvy gains accelerated approval in U.S. for advanced urothelial cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...